---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Clinical trials questions"
description: "Clinical trials questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How was the Trelegy IMPACT trial in COPD designed? Trelegy vs Breo and Anoro: how much were COPD exacerbations reduced (IMPACT)? Does Trelegy reduce severe (hospitalized) COPD exacerbations vs Breo and Anoro (IMPACT)? Does Trelegy delay the first COPD exacerbation vs Breo and Anoro (IMPACT)? 9 further questions follow. 13 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Clinical trials questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications](https://www.evicenter.com/medical-information/trelegy-ellipta).

## Clinical trials

<a id="trelegy-impact-design"></a>

### How was the Trelegy IMPACT trial in COPD designed?

> “The IMPACT trial was a 52-week, randomized, double-blind, parallel-group study that evaluated the efficacy and safety of TRELEGY 100 vs BREO 100, an ICS/LABA, and vs ANORO, a LAMA/LABA, in symptomatic patients with a history of 1 or more moderate or severe COPD exacerbations in the previous year. Exacerbations were moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required. At screening, patients with COPD (N=10,355, mean age: 65 years) had a mean postbronchodilator percent predicted FEV1 of 45.5% and a mean postbronchodilator FEV1/FVC ratio of 0.47.”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=The%20IMPACT%20trial%20was%20a,postbronchodilator%20FEV1%2FFVC%20ratio%20of%200.47.)

> “Exacerbations were 
> defined as worsening of 2 or more major symptoms (dyspnea, sputum volume, and sputum 
> purulence) or worsening of any 1 major symptom together with any 1 of the following minor 
> symptoms: sore throat, colds (nasal discharge and/or nasal congestion), fever without other 
> cause, and increased cough or wheeze for at least 2 consecutive days. Exacerbations were 
> considered to be moderate severity if treatment with systemic corticosteroids and/or antibiotics 
> was required and were considered to be severe if resulted in hospitalization or death.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 37, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=37)

Note: IMPACT is Trial 3 of the Prescribing Information; the second passage is the label's definition of an exacerbation in that trial.

<a id="trelegy-fulfil-design"></a>

### How was the Trelegy FULFIL trial in COPD designed?

> “The FULFIL trial was a 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-US study that evaluated the efficacy and safety of once-daily TRELEGY 100 vs twice-daily SYMBICORT TURBUHALER 400/12* in patients with COPD. A subset of 430 patients continued on blinded treatment through an extension phase for up to 52 weeks. At screening, patients (N=1810, mean age: 64 years) with COPD had a mean postbronchodilator percent predicted FEV1 of 45.3% and a mean postbronchodilator FEV1/FVC ratio of 0.45. In the 12 months prior to screening, 35% of patients had no moderate to severe exacerbations. Exacerbations were moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=The%20FULFIL%20trial%20was%20a,severe%20if%20hospitalization%20was%20required.)

On the page, select: FULFIL study description1,4

> “*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily<sup>2,3</sup>.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=hospitalization%20was%20required.-,%2ASYMBICORT%20TURBUHALER%20400%2F12%20is%20a%20non%2DUS%20formulation%20that%20delivers%20budesonide%2Fformoterol,via%201%20inhalation%20taken%20twice)

On the page, select: FULFIL study description1,4

## Study results

<a id="trelegy-impact-exacerbations"></a>

### Trelegy vs Breo and Anoro: how much were COPD exacerbations reduced (IMPACT)?

> “Trial 3 was a randomized, multicenter, double-blind, parallel-group, 52-week treatment trial 
> comparing the clinical efficacy of TRELEGY ELLIPTA 100/62.5/25 mcg with the fixed-dose 
> combinations of fluticasone furoate/vilanterol 100/25 mcg and umeclidinium/vilanterol 
> 62.5/25 mcg. A total of 10,355 subjects with COPD with a history of 1 or more moderate or 
> severe exacerbations in the prior 12 months were randomized (2:2:1) to receive TRELEGY 
> ELLIPTA, fluticasone furoate/vilanterol, or umeclidinium/vilanterol administered once daily.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “TRELEGY significantly reduced the annual rate of moderate to severe exacerbations by 15% vs BREO (P<0.001) and by 25% vs ANORO (P<0.001).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=TRELEGY%20significantly%20reduced%20the%20annual,and%20by%2025%25%20vs%20ANORO)

> “Table 5. Moderate and Severe Chronic Obstructive Pulmonary Disease Exacerbations 
> (Trial 3)<sup>a</sup> 
> Treatment 
> n 
> Mean Annual 
> Rate 
> (exacerbations/y) 
> Rate Ratio vs. 
> Comparator 
> (95% CI) 
> % Reduction in 
> Exacerbation 
> Rate 
> (95% CI) 
> P Value 
> TRELEGY 
> ELLIPTA 
> 4,145 
> 0.91 
>
>
>
> FF/VI 
> 4,133 
> 1.07 
> 0.85 
> (0.80, 0.90) 
> 15 
> (10, 20) 
> P<0.001 
> UMEC/VI 
> 2,069 
> 1.21 
> 0.75 
> (0.70, 0.81) 
> 25 
> (19, 30) 
> P<0.001 
> FF/VI = Fluticasone furoate/vilanterol 100/25 mcg, UMEC/VI = Umeclidinium/vilanterol 
> 62.5/25 mcg. 
> <sup>a</sup> On-treatment analyses excluded exacerbation data collected after discontinuation of study 
> treatment.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 38, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=38)

Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. Table 5 lists, for each arm, n, the mean annual rate, the rate ratio vs. comparator (95% CI), the percent reduction (95% CI), and the P value.

<a id="trelegy-impact-hospitalizations"></a>

### Does Trelegy reduce severe (hospitalized) COPD exacerbations vs Breo and Anoro (IMPACT)?

> “Trial 3 was a randomized, multicenter, double-blind, parallel-group, 52-week treatment trial 
> comparing the clinical efficacy of TRELEGY ELLIPTA 100/62.5/25 mcg with the fixed-dose 
> combinations of fluticasone furoate/vilanterol 100/25 mcg and umeclidinium/vilanterol 
> 62.5/25 mcg. A total of 10,355 subjects with COPD with a history of 1 or more moderate or 
> severe exacerbations in the prior 12 months were randomized (2:2:1) to receive TRELEGY 
> ELLIPTA, fluticasone furoate/vilanterol, or umeclidinium/vilanterol administered once daily.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “TRELEGY demonstrated a reduction of 13% in annual rate of severe exacerbations vs BREO (P=NS) and a significant 34% reduction vs ANORO (P<0.001).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=TRELEGY%20demonstrated%20a%20reduction%20of,significant%2034%25%20reduction%20vs%20ANORO)

> “Treatment with TRELEGY ELLIPTA reduced the on-treatment annual rate of severe COPD 
> exacerbations (i.e., requiring hospitalization or resulting in death) by 13% compared with 
> fluticasone furoate/vilanterol (95% CI: -1, 24; P = 0.064) which was not statistically significant. 
> Treatment with TRELEGY ELLIPTA statistically significantly reduced the on-treatment annual 
> rate of severe COPD exacerbations by 34% compared with umeclidinium/vilanterol (95% CI: 22, 
> 44; P<0.001).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 38, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=38)

Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. The label defines a severe exacerbation as one requiring hospitalization or resulting in death.

<a id="trelegy-impact-time-to-exacerbation"></a>

### Does Trelegy delay the first COPD exacerbation vs Breo and Anoro (IMPACT)?

> “Trial 3 was a randomized, multicenter, double-blind, parallel-group, 52-week treatment trial 
> comparing the clinical efficacy of TRELEGY ELLIPTA 100/62.5/25 mcg with the fixed-dose 
> combinations of fluticasone furoate/vilanterol 100/25 mcg and umeclidinium/vilanterol 
> 62.5/25 mcg. A total of 10,355 subjects with COPD with a history of 1 or more moderate or 
> severe exacerbations in the prior 12 months were randomized (2:2:1) to receive TRELEGY 
> ELLIPTA, fluticasone furoate/vilanterol, or umeclidinium/vilanterol administered once daily.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “Treatment with TRELEGY ELLIPTA statistically significantly decreased the risk of a 
> moderate/severe COPD exacerbation as measured by time to first exacerbation when compared 
> with fluticasone furoate/vilanterol (14.8%; 95% CI: 9.3, 19.9; P<0.001) and 
> umeclidinium/vilanterol (16.0%; 95% CI: 9.4, 22.1; P<0.001).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 38, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=38)

Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses.

<a id="trelegy-impact-lung-function"></a>

### How much does Trelegy improve COPD lung function vs Breo and Anoro (IMPACT)?

> “Trial 3 was a randomized, multicenter, double-blind, parallel-group, 52-week treatment trial 
> comparing the clinical efficacy of TRELEGY ELLIPTA 100/62.5/25 mcg with the fixed-dose 
> combinations of fluticasone furoate/vilanterol 100/25 mcg and umeclidinium/vilanterol 
> 62.5/25 mcg. A total of 10,355 subjects with COPD with a history of 1 or more moderate or 
> severe exacerbations in the prior 12 months were randomized (2:2:1) to receive TRELEGY 
> ELLIPTA, fluticasone furoate/vilanterol, or umeclidinium/vilanterol administered once daily.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “TRELEGY demonstrated a significant 97 mL improvement vs BREO (P<0.001) and a significant 54 mL improvement vs ANORO (P<0.001).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=TRELEGY%20demonstrated%20a%20significant%2097,54%20mL%20improvement%20vs%20ANORO)

> “The mean change 
> from baseline in trough (predose) FEV1 at Week 52 was 97 mL for TRELEGY ELLIPTA 
> compared with fluticasone furoate/vilanterol (95% CI: 85, 109; P<0.001) and 54 mL for 
> TRELEGY ELLIPTA compared with umeclidinium/vilanterol (95% CI: 39, 69; P<0.001).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 36, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=36)

Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. The measure is the change from baseline in trough FEV1 at Week 52.

<a id="trelegy-impact-quality-of-life"></a>

### Does Trelegy improve COPD quality of life vs Breo and Anoro (IMPACT)?

> “Trial 3 was a randomized, multicenter, double-blind, parallel-group, 52-week treatment trial 
> comparing the clinical efficacy of TRELEGY ELLIPTA 100/62.5/25 mcg with the fixed-dose 
> combinations of fluticasone furoate/vilanterol 100/25 mcg and umeclidinium/vilanterol 
> 62.5/25 mcg. A total of 10,355 subjects with COPD with a history of 1 or more moderate or 
> severe exacerbations in the prior 12 months were randomized (2:2:1) to receive TRELEGY 
> ELLIPTA, fluticasone furoate/vilanterol, or umeclidinium/vilanterol administered once daily.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “42% of patients receiving TRELEGY had a decrease from baseline of 4 or more in SGRQ total score vs 34% of patients receiving BREO (P<0.001) and 34% of patients receiving ANORO (P<0.001).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=42%25%20of%20patients%20receiving%20TRELEGY,34%25%20of%20patients%20receiving%20ANORO)

> “In Trial 3, the on-treatment responder rate at 
> Week 52 was statistically significantly greater for subjects treated with TRELEGY ELLIPTA 
> (42%) compared with fluticasone furoate/vilanterol (34%; OR: 1.41; 95% CI: 1.29, 1.55; 
> P<0.001) and compared with umeclidinium/vilanterol (34%; OR: 1.41; 95% CI: 1.26, 1.57; 
> P<0.001).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 38, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=38)

Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. SGRQ is the St. George's Respiratory Questionnaire; a responder had a decrease from baseline of 4 or more in total score.

<a id="trelegy-impact-rescue-use"></a>

### Do COPD patients on Trelegy use less rescue medication (IMPACT)?

> “In Trial 3, subjects treated with 
> TRELEGY ELLIPTA on average used less rescue medication (mean number of uses per day and 
> percentage of rescue-free 24-hour periods) compared with subjects treated with fluticasone 
> furoate/vilanterol or umeclidinium/vilanterol over the course of the 52-week study.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 39, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=39)

Note: IMPACT is Trial 3 of the Prescribing Information. The label gives no figures for this endpoint.

<a id="trelegy-components-trials-lung-function"></a>

### How did Trelegy's components improve COPD lung function at 12 weeks (Trials 1, 2)?

> “Trials 1 and 2 were multicenter, randomized, double-blind, parallel-group, 12-week treatment 
> trials in subjects with COPD. Across both trials, a total of 412 subjects received coadministration 
> of umeclidinium 62.5 mcg + fluticasone furoate/vilanterol 100/25 mcg, the components of 
> TRELEGY ELLIPTA.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 33, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=33)

> “Lung Function: In Trials 1 and 2, the primary endpoint was change from baseline in trough 
> (predose) FEV1 at Day 85 (defined as the mean of the FEV1 values obtained at 23 and 24 hours 
> after the previous dose on Day 84). For both COPD trials, umeclidinium + fluticasone 
> furoate/vilanterol demonstrated a statistically significant increase relative to placebo + 
> fluticasone furoate/vilanterol (Table 4); similar results were demonstrated for the secondary 
> endpoint of the weighted mean FEV1 (0 to 6 hours postdose) on Day 84 (Table 4).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 34, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=34)

> “Table 4. Least Squares Mean Change from Baseline in Trough FEV1 and Weighted Mean 
> FEV1 (0-6 h) at Week 12 (Days 84/85) 
> Treatment 
> n 
> Trough FEV1 (mL)<sup>a</sup> 
> Weighted Mean FEV1 (0-6 h) 
> (mL)<sup>b</sup> 
> Difference from Placebo + 
> FF/VI 
> (95% CI) 
> Difference from Placebo + 
> FF/VI 
> (95% CI) 
> Trial 1 
>
>
>
>
> UMEC + FF/VI 
> 206 
> 124 
> 153 
>
>
> (93, 154) 
> (118, 187) 
> Trial 2 
>
>
>
> UMEC + FF/VI 
> 206 
> 122 
> 147 
>
>
> (91, 152) 
> (114, 179) 
> FEV1 = Forced Expiratory Volume in 1 Second, FF/VI = Fluticasone Furoate/Vilanterol 
> 100/25 mcg, UMEC = Umeclidinium 62.5 mcg. 
> <sup>a</sup> At Day 85. 
> <sup>b</sup> At Day 84. 
> <sup>c</sup> For Placebo + FF/VI: Trial 1, n = 206; Trial 2, n = 206.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 34, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=34)

Note: Trials 1 and 2 tested umeclidinium added to fluticasone furoate/vilanterol from separate inhalers. Table 4 gives, for each trial, n, then the difference from placebo + FF/VI in trough FEV1 and in weighted mean FEV1 (0-6 h), with each 95% CI on the line below.

<a id="trelegy-onset"></a>

### How soon did Trelegy's components improve COPD lung function vs FF/VI (Trials 1, 2)?

> “Greater least squares (LS) mean changes from baseline in FEV1 over time were demonstrated for 
> the umeclidinium + fluticasone furoate/vilanterol treatment group compared with the placebo + 
> fluticasone furoate/vilanterol treatment group starting at 15 minutes postdose on Day 1.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 34, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=34)

Note: The passage concerns Trials 1 and 2, which tested umeclidinium added to fluticasone furoate/vilanterol, the components of TRELEGY ELLIPTA, against placebo added to fluticasone furoate/vilanterol.

<a id="trelegy-fulfil-lung-function"></a>

### How much did Trelegy improve COPD lung function vs Symbicort Turbuhaler (FULFIL)?

> “The FULFIL trial was a 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-US study that evaluated the efficacy and safety of once-daily TRELEGY 100 vs twice-daily SYMBICORT TURBUHALER 400/12* in patients with COPD.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=The%20FULFIL%20trial%20was%20a,400%2F12%2A%20in%20patients%20with%20COPD.)

On the page, select: FULFIL study description1,4

> “*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily<sup>2,3</sup>.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=hospitalization%20was%20required.-,%2ASYMBICORT%20TURBUHALER%20400%2F12%20is%20a%20non%2DUS%20formulation%20that%20delivers%20budesonide%2Fformoterol,via%201%20inhalation%20taken%20twice)

On the page, select: FULFIL study description1,4

> “Patients on TRELEGY experienced significantly improved lung function by 171 mL vs an ICS/LABA<sup>1*</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Patients%20on%20TRELEGY%20experienced%20significantly,by%20171%20mL%20vs%20an)

On the page, select: FULFIL study description1,4

> “Co-primary endpoint: change from baseline in trough FEV1 at Week 24<sup>1,4</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Co%2Dprimary%20endpoint%3A%20change%20from%20baseline%20in%20trough%20FEV1%20at%20Week)

On the page, select: FULFIL study description1,4

> “In an additional analysis (not adjusted for multiplicity): TRELEGY demonstrated a 179-mL improvement in lung function vs SYMBICORT TURBUHALER 400/12.*”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=In%20an%20additional%20analysis%20%28not,function%20vs%20SYMBICORT%20TURBUHALER%20400%2F12.%2A)

On the page, select: See lung function improvement at 52 weeks (extension data)

> “LS mean change from baseline in trough FEV1 at Week 52 was 126 mL for TRELEGY (n=183) and –53 mL for SYMBICORT TURBUHALER 400/12* (n=171).”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=LS%20mean%20change%20from%20baseline,for%20SYMBICORT%20TURBUHALER%20400%2F12%2A%20%28n%3D171%29.)

On the page, select: See lung function improvement at 52 weeks (extension data)

Note: The 171 mL difference is at Week 24 against SYMBICORT TURBUHALER 400/12, the ICS/LABA comparator in FULFIL. The Week 52 figures come from the extension phase.

<a id="trelegy-fulfil-quality-of-life"></a>

### Does Trelegy improve COPD quality of life vs Symbicort Turbuhaler (FULFIL)?

> “The FULFIL trial was a 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-US study that evaluated the efficacy and safety of once-daily TRELEGY 100 vs twice-daily SYMBICORT TURBUHALER 400/12* in patients with COPD.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=The%20FULFIL%20trial%20was%20a,400%2F12%2A%20in%20patients%20with%20COPD.)

On the page, select: FULFIL study description1,4

> “Patients taking TRELEGY were more likely to show an improvement in quality of life at Week 24 vs SYMBICORT TURBUHALER 400/12,* as measured by SGRQ.<sup>1</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Patients%20taking%20TRELEGY%20were%20more,TURBUHALER%20400%2F12%2C%2A%20as%20measured%20by)

On the page, select: FULFIL study description1,4

> “Co-primary endpoint: change from baseline in SGRQ total score at Week 24<sup>1</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Co%2Dprimary%20endpoint%3A%20change%20from%20baseline%20in%20SGRQ%20total%20score%20at%20Week)

On the page, select: FULFIL study description1,4

> “In an additional analysis (not adjusted for multiplicity): TRELEGY (n=182) demonstrated an improvement from baseline in SGRQ total score of –4.6 units compared with –1.9 units for SYMBICORT TURBUHALER 400/12* (n=174) at Week 52; difference –2.7 (95% CI: –5.5, 0.2).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=In%20an%20additional%20analysis%20%28not%20adjusted%20for%20multiplicity%29%3A%20TRELEGY%20%28n%3D182%29,difference%20%E2%80%932.7%20%2895%25%20CI%3A%20%E2%80%935.5%2C)

On the page, select: See quality-of-life improvements at 52 weeks (extension data)

> “The SGRQ responder rate at Week 52 was greater for TRELEGY (44%, 91/209) compared with SYMBICORT TURBUHALER 400/12* (33%, 73/219) with an OR of 1.5 (95% CI: 1.01, 2.24).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=The%20SGRQ%20responder%20rate%20at,of%201.5%20%2895%25%20CI%3A%201.01%2C)

On the page, select: See quality-of-life improvements at 52 weeks (extension data)

Note: The page presents the Week 24 SGRQ results in an image only. The Week 52 figures come from the extension phase. SYMBICORT TURBUHALER 400/12 is a non-US budesonide/formoterol formulation.

<a id="trelegy-fulfil-exacerbations"></a>

### Did Trelegy reduce COPD exacerbations vs Symbicort Turbuhaler (FULFIL)?

> “The FULFIL trial was a 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-US study that evaluated the efficacy and safety of once-daily TRELEGY 100 vs twice-daily SYMBICORT TURBUHALER 400/12* in patients with COPD.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=The%20FULFIL%20trial%20was%20a,400%2F12%2A%20in%20patients%20with%20COPD.)

On the page, select: FULFIL study description1,4

> “In the 12 months prior to screening, 35% of patients had no moderate to severe exacerbations.”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=In%20the%2012%20months%20prior,no%20moderate%20to%20severe%20exacerbations.)

On the page, select: FULFIL study description1,4

> “Patients on TRELEGY experienced 35% reduction in exacerbation rate vs an ICS/LABA<sup>1*</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Patients%20on%20TRELEGY%20experienced%2035%25%20reduction%20in%20exacerbation%20rate%20vs%20an)

On the page, select: FULFIL study description1,4

> “Secondary endpoint: annual rate of moderate to severe exacerbations<sup>1</sup>
> Endpoint was not adjusted for multiplicity.<sup>4</sup>”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=Secondary%20endpoint%3A%20annual%20rate%20of,Endpoint%20was%20not%20adjusted%20for)

On the page, select: FULFIL study description1,4

Note: The ICS/LABA comparator in FULFIL was SYMBICORT TURBUHALER 400/12. SYMBICORT TURBUHALER 400/12 is a non-US budesonide/formoterol formulation.

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
